Leerink Swann Equities Analysts Boost Earnings Estimates for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) – Equities researchers at Leerink Swann lifted their FY2019 earnings per share (EPS) estimates for shares of Eli Lilly and in a research report issued to clients and investors on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings per share of $4.77 for the year, up from their prior forecast of $4.76. Leerink Swann currently has a “Market Perform” rating and a $93.00 target price on the stock.
A number of other analysts have also issued reports on LLY. Barclays PLC raised their target price on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Citigroup Inc. reaffirmed a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a report on Tuesday, July 4th. Zacks Investment Research raised Eli Lilly and from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $96.00 target price (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 target price (up previously from $90.00) on shares of Eli Lilly and in a report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $89.12.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/24/leerink-swann-equities-analysts-boost-earnings-estimates-for-eli-lilly-and-company-lly.html.
Eli Lilly and (LLY) traded down 2.34% during trading on Tuesday, hitting $85.14. The stock had a trading volume of 7,318,417 shares. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The company’s 50-day moving average is $84.58 and its 200 day moving average is $82.25. The firm has a market cap of $89.82 billion, a PE ratio of 36.84 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS.
A number of hedge funds have recently made changes to their positions in the stock. Ronna Sue Cohen boosted its stake in Eli Lilly and by 0.4% in the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares in the last quarter. Accredited Investors Inc. boosted its stake in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares in the last quarter. Sunbelt Securities Inc. boosted its stake in Eli Lilly and by 0.5% in the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its stake in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares in the last quarter. Finally, Oakworth Capital Inc. boosted its stake in Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after buying an additional 20 shares in the last quarter. 75.61% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is owned by insiders.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.39%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is 90.04%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.